Flecainide Monitoring Guidelines
For patients on flecainide, PR and QRS intervals should be monitored, with QRS widening not permitted to exceed 150% of the pretreatment QRS duration, and plasma trough levels should be maintained between 0.2-1.0 mcg/mL, with levels above 0.7-1.0 mcg/mL requiring close monitoring. 1
Initial Monitoring Requirements
Baseline Assessment
- 12-lead ECG to document baseline PR and QRS intervals
- Assessment for contraindications:
Dose Titration and Monitoring
- Initial dose: 50 mg every 12 hours
- Maximum maintenance dose: 150 mg every 12 hours 1
- Obtain ECG and plasma trough flecainide levels at presumed steady state (after at least 5 doses) 3
- Measure trough levels (less than one hour pre-dose) 3
Ongoing Monitoring Parameters
ECG Monitoring
- Monitor PR and QRS intervals regularly
- QRS widening should not exceed 150% of pretreatment QRS duration 4
- Exercise testing may be helpful to detect QRS widening that occurs only at rapid heart rates (use-dependent conduction slowing) 4
Plasma Level Monitoring
- Therapeutic range: 0.2-1.0 mcg/mL 3, 5
- Trough plasma levels between 0.2-0.7 mcg/mL are generally effective with lower risk of adverse effects 3
- Levels approaching or exceeding 1.0 mcg/mL are associated with increased risk of cardiac adverse events 3
Frequency of Monitoring
- For the first year on therapy: 12-lead ECG and plasma trough flecainide level at each clinical follow-up 3
- More frequent monitoring is required in:
- Patients with severe renal impairment (creatinine clearance ≤35 mL/min/1.73 m²)
- Patients with hepatic disease
- Patients on concurrent amiodarone therapy (reduce flecainide dose by 50%)
- Patients with congestive heart failure 3
Special Populations Requiring Enhanced Monitoring
Renal Impairment
- For severe renal impairment: Initial dose of 100 mg once daily (or 50 mg twice daily)
- Frequent plasma level monitoring required
- Dosage increases should be made very cautiously when plasma levels have plateaued (after more than 4 days) 3
Drug Interactions
- When flecainide is given with amiodarone, reduce usual flecainide dose by 50% and monitor closely 3
- Monitor digoxin concentrations when administering with flecainide 6, 7
- Monitor for interactions with other medications:
- Ritonavir, saquinavir, tipranavir
- QT-prolonging drugs 1
Signs of Toxicity to Monitor For
Cardiac Effects
- Proarrhythmia (particularly atrial flutter with 1:1 AV conduction)
- QT prolongation
- Torsades de pointes (rare)
- Worsening heart failure
- Bradycardia 1, 8
Non-Cardiac Effects
- Dizziness (most common)
- Visual disturbances (blurred vision, difficulty focusing)
- Gastrointestinal complaints 8, 9
Common Pitfalls and Caveats
- Flecainide should be avoided in patients with structural heart disease, including ischemic heart disease, due to increased risk of proarrhythmia 1, 8
- In some patients, plasma levels can increase rapidly despite stable dosing, requiring close monitoring 3
- Small changes in dose may lead to disproportionate increases in plasma levels 3
- It may take 5-7 days of constant dosing before reaching steady state 10
- Arrhythmogenic effects may occur in some patients, particularly those with severe coronary artery disease or cardiomyopathy 11
- Flecainide has a narrow therapeutic range, making monitoring essential 10